Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • JnJ hip implants:...

    JnJ hip implants: CDSCO orders compensation of over Rs 2 crore for 2 more patients

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-05-02T11:23:53+05:30  |  Updated On 2 May 2019 11:23 AM IST
    JnJ hip implants: CDSCO orders compensation of over Rs 2 crore for 2 more patients

    With these two cases, the Central Drugs Standard Control Organisation (CDSCO) has so far ordered compensation to four patients, based on the recommendations of the Central Expert Committee and the state-level committee.


    NEW DELHI: The country's drug regulator has directed pharmaceutical company Johnson & Johnson(JnJ) to pay compensation to two more patients who received faulty hip implants made by the firm, a senior health ministry official said Tuesday.


    The official said both the patients are from Uttar Pradesh and the JnJ has been asked to give them Rs 90.26 lakh and Rs 1.01 crore.


    With these two cases, the Central Drugs Standard Control Organisation (CDSCO) has so far ordered compensation to four patients, based on the recommendations of the Central Expert Committee and the state-level committee.


    Earlier, the regulator had directed Johnson & Johnson to pay compensation to one patient each in Mumbai (in March) and Delhi (April).


    The CDSCO has directed the compensation to be paid within 30 days from the date of receipt of the order.


    In November last year, the Union Health Ministry approved a formula for determination of compensation for patients who had received, prior to August 2010, ASR hip implants manufactured by DePuy International Limited, UK, a Johnson & Johnson subsidiary.


    According to the formula, thousands of patients implanted with US pharmaceutical major Johnson and Johnson's (J&J) articular surface replacement (ASR) hip implant, were to be compensated between Rs 30 lakh to Rs 1.23 crore.


    The company J&J recalled the faulty metal-on-metal ASR hip implants in 2010 globally after studies red-flagged the high rate of revision surgeries. The government in 2017 constituted the central expert panel to investigate the complaints about ASR hip implant devices.


    The committee headed by Dr Arun Kumar Agarwal, Ex-Dean and Professor of ENT, Maulana Azad Medical College, stated the pharmaceutical giant "suppressed" facts on the harm of surgeries, and recommended that patients be compensated.


    Following this, in October 2018, the government had constituted the five-member central expert committee to determine the quantum of compensation to be given to the patients.


    Also Read: JnJ Faulty Hip Implants Case: Mumbai police reopens the investigation

    CDSCO.JnJCentral Drugs Standard Control OrganisationDePuy InternationalFaulty hip implantship implants compensationJnJjnj compensationJnJ hip implants caseJohnsonJohnson and JohnsonMaulana Azad Medical Collegeotorhinolaryngology
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok